News | ECG | October 13, 2023

Cardiomatics Obtains the World’s 1st MDR Certification for AI-based ECG Interpretation and Implements new Functionalities

The software updates introduce fast-track analysis and a user-friendly layout for quicker review of ECG findings, enhancing efficiency for medical professionals 

The software updates introduce fast-track analysis and a user-friendly layout for quicker review of ECG findings, enhancing efficiency for medical professionals

October 13, 2023 — The newly MDR-certified Cardiomatics solution is accurate, fast and easy-to-use AI-based standalone software for ECG analysis. The Cardiomatics ECG interpretation platform is used by more than 200 clinics and 1,000 medical professionals. The platform has shown how clinical-grade and validated AI can be used to automate the ECG analysis workflow allowing medical professionals to save hours per day and focus on clinical decisions. 

The Medical Device Regulation (MDR) is the EU's most recent and comprehensive framework for the approval of medical devices. These stricter requirements were introduced to improve the quality, safety and reliability of medical devices, strengthen transparency and information for patients and enhance vigilance and market surveillance. 

"Cardiomatics makes diagnostics much faster and more productive. This innovative AI-based ECG interpretation platform is MDR-certified now - we can be sure of quality, precision, and commitment to patient well-being" - underlines Prof. Dr. David Duncker, Electrophysiologist, Head of Hannover Heart Rhythm Center, Chair #EHRA_ESC Digital and E-Communication Committee and Cardiomatics Scientific Board Member. 

Obtaining the MDR certification positions Cadiomatics well to continue expanding the use of its unique AI platform across Europe.  

Empowering cardiac healthcare with new functionalities 

In the newest v5 of the standalone software, Cardiomatics has implemented a major feature: Atrioventricular block detection of 2nd and 3rd degrees. Detecting AV blocks in ECG signals is vital for diagnosing and managing heart rhythm disorders, assessing patient risk, guiding treatment decisions, and providing valuable prognostic information. Apart from AV block detection, Cardiomatics now includes fast-track analysis and a new layout that allows medical professionals to review the detailed findings from the Cardiomatics analysis faster. 

"Cardiomatics' achievement of the introduction of AV block detection in Cardiomatics v.5 and the world’s first MDR Certification for AI-based ECG interpretation mark the next pivotal moment for our company. We are confident that these advancements will empower healthcare professionals with the most precise and insightful tools for heart rhythm disorder diagnostics and treatment decisions." - says Rafał Samborski, CEO of Cardiomatics. 

For more information: www.cardiomatics.co


Related Content

Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Feature | Heart Failure | Kyle Hardner

Could a link between the heart, brain and immune system help reduce the occurrence of heart attacks and lessen the ...

Home May 04, 2026
Home
News | Heart Failure

April 21, 2026 — Nuwellis, Inc. has announced a software update to its Aquadex SmartFlow ultrafiltration platform. The ...

Home April 23, 2026
Home
News | Heart Failure

March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein ...

Home April 06, 2026
Home
News | Heart Failure

March 24, 2026 — New research shows that small improvements to sleep, diet quality and physical activity, made in ...

Home March 25, 2026
Home
News | Heart Failure

March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of ...

Home March 16, 2026
Home
Feature | Heart Failure | Rohit Sood, MD, PhD

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect ...

Home February 12, 2026
Home
News | Heart Failure

Feb. 3, 2026 — Bristol Myers Squibb has launched "Change the Target. Change What’s Possible," an educational campaign ...

Home February 03, 2026
Home
News | Heart Failure

Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac ...

Home January 27, 2026
Home
Subscribe Now